Multiple mutations in hepatitis C virus NS5A domain II are required to confer a significant level of resistance to alisporivir
about
Chaperones in hepatitis C virus infectionHost-Targeting Agents to Prevent and Cure Hepatitis C Virus InfectionCyclophilin Inhibitors Remodel the Endoplasmic Reticulum of HCV-Infected Cells in a Unique Pattern Rendering Cells Impervious to a ReinfectionInfection Counter: Automated Quantification of in Vitro Virus Replication by Fluorescence MicroscopyCharacterization of the Anti-HCV Activities of the New Cyclophilin Inhibitor STG-175Virus-host interactomics: new insights and opportunities for antiviral drug discoveryRandomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II).The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance.Novel indole-2-carboxamide compounds are potent broad-spectrum antivirals active against western equine encephalitis virus in vivo.Profile of alisporivir and its potential in the treatment of hepatitis C.Hepatitis C NS5A protein: two drug targets within the same protein with different mechanisms of resistance.Cyclophilin and NS5A inhibitors, but not other anti-hepatitis C virus (HCV) agents, preclude HCV-mediated formation of double-membrane-vesicle viral factoriesThe Novel Cyclophilin Inhibitor CPI-431-32 Concurrently Blocks HCV and HIV-1 Infections via a Similar Mechanism of Action.Phenotypic analysis of NS5A variant from liver transplant patient with increased cyclosporine susceptibilityCyclophilin inhibitors: an emerging class of therapeutics for the treatment of chronic hepatitis C infectionAntiviral drug discovery: broad-spectrum drugs from nature.The role of immunophilins in viral infection.Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection.A pharmacokinetic-viral kinetic model describes the effect of alisporivir as monotherapy or in combination with peg-IFN on hepatitis C virologic response.Modeling viral kinetics and treatment outcome during alisporivir interferon-free treatment in hepatitis C virus genotype 2 and 3 patients.
P2860
Q26771251-AE0103B8-95C8-48BC-9DFD-3472816AEC3AQ26779128-5B7BD814-6730-4696-B565-4E691E55E710Q27468931-480353B5-7346-4A95-9A6F-FE5803E57B1BQ28364857-6D08A643-8F91-4204-AC8F-A4C52D1AEB18Q28551538-474870CD-AB07-449A-BAC2-CBF93369538DQ28652236-402113A3-70C6-41F3-A3EE-F20169FE381EQ33424900-13A5F48B-D91C-40FD-884D-0EB715EF4CE2Q33797891-5F8AE262-09ED-4353-AB85-0C4C3E8FA4F1Q34261735-11A082B1-DA89-4441-BA1D-E2EF3B4D447FQ34329744-B7FD5B7C-D80A-4252-96D4-12091DD59D78Q34332546-4FBE56AF-0E59-4712-9AE0-3BF54A8F0177Q35385005-D5968923-DC9A-49A3-9517-3DA15DFE16FAQ35742761-FEDB77B4-C2FB-43EA-AF17-2D6C32A91B93Q37144087-B9CE4FC3-0E5D-4283-A727-5C6F21B81141Q38064282-3C9732D5-D1A5-4E74-9C9C-59C733806CA5Q38260235-7ED098FC-C353-4E4E-8726-56447DA4A6B1Q38274889-2135A021-BB45-45CB-B168-D554F8C8B73BQ38990715-F9F7A533-6D13-4ADB-ADB7-F01D812FEAE0Q42196934-5C531850-FC1F-46C2-BCD3-8AB546D8F836Q42246268-17ADDDA2-5552-4F77-9F42-CB72AA7FE150
P2860
Multiple mutations in hepatitis C virus NS5A domain II are required to confer a significant level of resistance to alisporivir
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Multiple mutations in hepatiti ...... l of resistance to alisporivir
@en
Multiple mutations in hepatiti ...... of resistance to alisporivir.
@nl
type
label
Multiple mutations in hepatiti ...... l of resistance to alisporivir
@en
Multiple mutations in hepatiti ...... of resistance to alisporivir.
@nl
prefLabel
Multiple mutations in hepatiti ...... l of resistance to alisporivir
@en
Multiple mutations in hepatiti ...... of resistance to alisporivir.
@nl
P2093
P2860
P356
P1476
Multiple mutations in hepatiti ...... l of resistance to alisporivir
@en
P2093
Barrie Wilkinson
Jose A Garcia-Rivera
Matthew A Gregory
Michael Bobardt
Philippe A Gallay
Sam Hopkins
Udayan Chatterji
P2860
P304
P356
10.1128/AAC.00919-12
P407
P577
2012-07-16T00:00:00Z